Comparative Pharmacology
Head-to-head clinical analysis: BELBUCA versus BUTRANS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELBUCA versus BUTRANS.
BELBUCA vs BUTRANS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
None Documented
None Documented
Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA.
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic